JNJ

Johnson & Johnson JNJ logo

NYSE Healthcare

$243.46

+0.94 (+0.39%)

Updated: 3/31/2026, 4:00:01 PM

Open

$243.01

High

$245.28

Low

$242.63

Prev Close

$242.49

Volume

1.84M

Price History

Why Is JNJ ▲ Up Today?

+0.39%

Full AI analysis generates after market close. Showing live price data.

Mar 31 ▲ +0.4% JNJ edges higher amid positive sentiment in healthcare sector

Mar 30 ▲ +0.3% JNJ edges higher amid positive sector sentiment and new data

Mar 27 ▲ +0.5% JNJ Up Slightly After FDA Approves Psoriasis Pill

Mar 26 — -0.0% JNJ Slightly Down Amidst Mixed Sector Performance

Mar 25 ▲ +2.0% JNJ Up on FDA Approval of Psoriasis Pill, Sector Strength

Mar 24 — -0.1% JNJ dips slightly despite sector gains, new FDA approval

Mar 23 ▼ -0.2% JNJ dips slightly despite positive news, sector weakness

Mar 20 ▼ -0.7% JNJ dips slightly despite positive news, new FDA approval

Mar 19 ▲ +0.1% J&J edges higher amid sector weakness, psoriasis pill approval

Mar 18 ▼ -0.5% JNJ dips slightly amid sector weakness, despite positive catalysts

Mar 17 ▼ -1.9% JNJ Declines Amid Sector Weakness and Profit-Taking

Mar 16 ▲ +0.8% JNJ Rises Slightly Amid Positive Sector Sentiment

Mar 13 ▼ -0.4% JNJ Down Slightly Despite Positive News, Broader Sector Weakness

Mar 12 ▼ -0.4% JNJ edges down slightly amid sector weakness

Mar 11 ▼ -0.3% JNJ Down Slightly Amid Sector Rotation and Mixed News

Mar 10 ▲ +0.5% JNJ Up Slightly Amidst Mixed Sector Performance

Mar 9 ▲ +0.9% JNJ Rises on FDA Approval of Multiple Myeloma Combo

Mar 6 ▼ -0.2% JNJ dips slightly despite FDA approval and analyst optimism

Mar 5 ▼ -2.3% JNJ dips amid sector weakness and competition concerns

Mar 4 ▼ -1.0% JNJ dips slightly amid mixed signals, AbbVie competition

Mar 3 ▼ -0.7% JNJ dips slightly amid sector weakness, AbbVie competition

Mar 2 ▼ -0.1% JNJ dips slightly amid sector weakness, AbbVie competition

Feb 27 ▲ +2.0% JNJ up 2.04% as healthcare sector rallies

Feb 26 ▼ -0.7% JNJ Down Slightly Despite Positive Sector News

Feb 25 ▼ -0.7% JNJ Down Slightly Despite Positive Sector News, Dividend King Status

Feb 24 — +0.1% JNJ edges higher amid sector weakness, positive news

Feb 23 ▲ +1.4% J&J Rises on Potential Orthopedics Sale, Cancer Drug Breakthrough

Feb 20 ▼ -2.0% J&J Down Nearly 2% Amid Sector Weakness, DePuy Synthes Sale Rumors

Feb 19 ▲ +0.7% JNJ edges higher on FDA nod, potential orthopedics sale

Feb 18 ▲ +0.3% JNJ edges higher on cancer drug progress, Pennsylvania plant plan

Financial Highlights

Income Statement

Revenue

$92.15B

Gross Profit

$62.73B

68.1% margin

Operating Income

$31.50B

34.2% margin

Net Income

$25.12B

27.3% margin

EPS (Diluted)

$10.36

Balance Sheet

Total Assets

$192.82B

Total Liabilities

$113.54B

Stockholders' Equity

$79.28B

Cash Flow

Operating Cash Flow

$24.20B

Investing Activities

-$20.42B

Net Cash Flow

-$1.75B

Highly Regarded Analysis

Updated Apr 10, 2026 • Refreshes daily

Rating

Highly Regarded

Risk

Low

Target

$254.60

Type

Standard

Executive Summary

Johnson & Johnson is a diversified healthcare company with a focus on pharmaceuticals and medical devices. The company has a long history of steady growth and dividend increases, but faces challenges including patent expirations, litigation, and pricing pressures. Analyst ratings are generally positive, with a consensus of 'Buy'.

Bull Case

The bull case for Johnson & Johnson is supported by steady revenue growth from areas like immunology, oncology, and MedTech, with large planned investments in US manufacturing, R&D, and technology. The company's diversified portfolio and strong cash flow generation make it a defensive investment.

Bear Case

The bear case for Johnson & Johnson is based on concerns about patent expirations, ongoing litigation, and pricing pressures. The loss of exclusivity for key pharmaceutical products and underwhelming performance from its pipeline and MedTech division raise questions about the company's ability to sustain organic revenue growth.

Technical Outlook

JNJ's stock has had a strong year, with a 16.4% return year-to-date and a 66.8% return over the last year. The stock traded between $240.54 and $244.20 on April 9, 2026.

Fundamental Health

Johnson & Johnson has a strong balance sheet with a low debt-to-equity ratio. Revenue grew 6.0% year-over-year to $94.2 billion in 2025, and earnings increased by 90.56%. The company's financial health criteria checks 4 out of 6 metrics.

Key Catalysts

Earnings and guidance
Product or service launches
Partnerships and M&A headlines

Sources

simplywall.st robinhood.com stocktitan.net stockanalysis.com simplywall.st investing.com public.com

This analysis was conducted by Highly Regarded's proprietary market analysis engine. It is not financial advice. Always do your own research and consult a financial advisor before making investment decisions.